A new treatment to prevent nerve damage from chemotherapy
A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy
This study is testing a new drug called SP16 to see if it can help prevent the painful nerve damage that some cancer survivors experience after chemotherapy, making life a little easier for those who have gone through treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serpin Pharma, LLC NIH-funded |
| Lab location | 1 site (Manassas, UNITED STATES) |
| Project ID | NIH-11069378 on NIH RePORTER |
What this research studies
This research investigates a novel drug called SP16, which aims to prevent chemotherapy-induced peripheral neuropathy (CIPN), a painful condition affecting many cancer survivors. SP16 works by activating a receptor that helps reduce inflammation and protect nerve tissues from damage caused by chemotherapy drugs, particularly taxanes. The study will assess the effectiveness of SP16 in alleviating symptoms of CIPN and improving the quality of life for patients who have undergone chemotherapy. By targeting the underlying causes of nerve damage, this approach seeks to provide a safer and more effective treatment option for those at risk of CIPN.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving chemotherapy, particularly those treated with taxanes and at risk of developing CIPN.
Not a fit: Patients who are not undergoing chemotherapy or those who have pre-existing neuropathy unrelated to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option to prevent painful nerve damage in cancer survivors undergoing chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for pain relief, but this specific approach with SP16 is novel and untested in clinical settings.
Where this research is happening
Manassas, UNITED STATES
- Serpin Pharma, LLC — Manassas, United States (Active)
Researchers
- Principal investigator: Gelber, Cohava — Serpin Pharma, LLC
- Study coordinator: Gelber, Cohava
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.